Hold with modest Underweight sizing (≤2% of portfolio) at knife-edge support; mechanical triggers govern re-engagement
Hold with modest Underweight sizing (≤2% of portfolio) is the correct architecture—directional call is Hold to avoid transaction friction and missed carry, but sizing is below benchmark to reflect asymmetric risk. The 9/16 binding lesson is dispositive: do not preemptively trim a low-beta defensive into structural support. The 9/21 reflection implements this through position discipline rather than active trim. If current position is already at or below ≤2% threshold, Hold with this sizing discipline is internally consistent. Re-engagement is governed entirely by mechanical triggers—no discretionary overrides.
| Position | Action |
|---|---|
| Default position sizing | ≤2% of portfolio (below benchmark weight for 0.32 beta name) |
| Confirmed weekly close below $84.00 with volume >5M | Trim 25-50% of remaining position; downgrade toward aggressive Underweight |
| Confirmed close below $82.00 with volume >5M | Exit residual entirely; wait for $80-82 structural floor defense |
CL at ~$85.93 presents a generational entry in a fundamentally excellent defensive compounder, where capitulation technicals converge with accelerating operating performance, aggressive capital return, and a 3-to-1 reward-to-risk skew over 12 months.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | $90.56 | bearish |
| close_200_sma | $87.45 | bearish |
| close_10_ema | $87.32 | bearish |
| rsi | 34.33 | bearish |
| macd | -1.23 (signal -1.04, histogram -0.19) | bearish |
| boll_lb | $85.12 | bearish |
| atr | 1.62 | neutral |
| vwma | $87.80 | bearish |
Support: 84 · 84.5 · 82 · 83 | Resistance: 87.32 · 87.45 · 88.77 · 90.56
CL exhibits textbook bearish alignment across all eight technical indicators: price at $85.93 sits below the 10 EMA ($87.32), 50 SMA ($90.56), and 200 SMA ($87.45), while MACD's bearish crossover continues accelerating with histogram at -0.19 and VWMA declining from $92.28 to $87.80 confirming institutional distribution. RSI at 34.33 approaches oversold but shows no bullish divergence yet; the close at $85.93 nearly tagged the lower Bollinger Band at $85.12 with today's low of $85.77. Recommended stance is to wait for confirmed reversal signals (price reclaim of 200 SMA on heavy volume with RSI bullish divergence or MACD histogram turning positive) before initiating long exposure.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Reclaim of $90.56 (50 SMA) with positive MACD histogram
Then: Upgrade to Overweight at full benchmark weight
Operating fundamentals are accelerating across all key metrics
EV: +15–20% total return over 12 months (target zone $94–$97 plus 2.44% dividend) · concedes: Near-term technicals are bearish with price below all moving averages, RSI at 34.33, and MACD histogram at -0.19; North America segment was soft in Q2 2026; S&P 100 deletion created mechanical selling overhang (~6.9% drawdown); Tariff exposure on Chinese-sourced inputs (~5% cost impact); Commodity/energy cost pressures on petrochemical-derived packaging; TTM P/E of 33.8x is distorted by Q4 2025 charge; forward multiple is appropriate metric; Q3 earnings in late October is a binary catalyst that could confirm or deny the NA inflection thesis
CL at $85.93 represents a dangerous setup where the operating margin is contracting (-210 bps YoY), the stock trades at a premium to its sector, the technicals show institutional distribution, and the bull thesis requires six independent assumptions to go right ahead of a binary Q3 earnings catalyst.
EV: -$71 (bear case target, representing -17% from current levels) · concedes: CL is an excellent company with category dominance in oral care; Gross margin did expand 140 bps, showing some pricing power exists; Dividend at $2.12 annualized is sustainable at current FCF levels; Beta of 0.323 provides defensive characteristics if market panic ensues; Sector rotation away from defensives could create re-entry opportunity at lower levels
→ vs conservative: Waiting to reclaim 200 SMA at $87.45 (only $1.50 away) after refusing to add at $85.93 is self-defeating behavioral pattern disguised as prudence; capitulation setup with intact fundamentals warrants buying weakness rather than chasing higher
→ vs conservative: 21x P/E premium is justified by scarcity value of Dividend King with 170% FCF conversion, not generic consumer staples comparison
→ vs conservative: S&P 100 mechanical selling is non-fundamental and creates temporary price-value disconnect; treating it as momentum breakdown misreads the catalyst
→ vs neutral: Trump-Xi tariff risk already priced into -6.9% drawdown over 30 sessions in 0.32 beta name; waiting for Q3 confirmation means competing with pension and dividend ETF buyers at $90+
→ vs neutral: Binary catalysts cited as hedging justification are already discounted; waiting for green light that doesn't change long-term thesis wastes 2 years of dividend income on 4-5% price giveback
→ vs conservative: Operating margin concerns misread SG&A growth as structural deterioration when it's the NA recovery premiumization playbook; gross margin trajectory confirms pricing power intact
Market Capitalization
$68.50 billion
P/E Ratio (TTM)
33.83
Forward P/E
20.95
PEG Ratio
1.59
Price to Book
290.30
Dividend Yield
2.44%
EPS (TTM)
$2.54
Forward EPS
$4.10
Beta
0.323
52-Week High
$99.33
52-Week Low
$74.55
50-Day Moving Average
$90.62
200-Day Moving Average
$88.16
Revenue (TTM)
$21.05 billion
Revenue YoY (Q2 2026)
+4.9%
Gross Margin (Q2 2026)
61.5%
Operating Margin
20.97%
Profit Margin
9.68%
EBITDA Margin
23.7%
Net Income (TTM)
$2.04 billion
ROA
15.84%
Total Assets
$16.79 billion
Total Liabilities
$16.22 billion
Stockholders' Equity
$236 million
Treasury Stock
$28.93 billion
Total Debt
$7.86 billion
Cash & Equivalents
$1.37 billion
Net Debt
$6.49 billion
Current Ratio
1.03
FCF (TTM)
$3.46 billion
Operating CF (Q2 2026)
$995 million
CapEx (Q2 2026)
$128 million
Free Cash Flow (Q2 2026)
$867 million
Dividends Paid (Q2 2026)
$462 million
Share Repurchases (Q2 2026)
$291 million
Goodwill
$3.10 billion
Diluted Shares Outstanding
802 million
Strengths
Concerns
Colgate-Palmolive is a high-quality defensive consumer staples name trading at a premium trailing P/E of 33.83x but with expected earnings recovery bringing forward P/E to 20.95x. Revenue growth re-accelerated to +4.9% YoY with gross margins expanding 140 bps to 61.5%, while the company generated $3.46B in TTM free cash flow and returned ~87% of FCF via dividends and buybacks. The stock is technically strong (above both 50-day and 200-day moving averages, near 52-week high of $99.33) with an extremely low beta of 0.32, making it suitable for defensive portfolios seeking income (2.44% yield) and capital appreciation.
Macro: Macro backdrop favors defensive dividend payers: Fed is on hold with 96% probability of no cuts in 2026, and US recession odds have receded to 8% (down 4pp week-over-week). Soft-landing consensus in place. However, geopolitical risks loom—the Sept 24 Trump-Xi summit poses tariff risk for CL given China sourcing and emerging-market exposure. Energy supply fragility (Saudi Aramco crude halt, Russia/Ukraine refinery strikes) keeps crude bid, pressuring input costs for packaging and freight. Sector-wide margin pressure is real, evidenced by P&G's $1.4B FY27 after-tax headwind.